Gyawali. MW. Gastroenterología, 4ed

Capítulo 14 Trastornos del estómago 141 33. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer . 2010;127:2893–2917. 34. Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health . 2016;4:e609–e616. 35. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet . 1993;341:1359–1362. 36. Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointest Oncol . 2011;2:77–84. 37. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol . 2004;15:1585–1595. 38. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow- up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol . 2012;19:1074–1080. 39. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol . 2008;26:620–625. 40. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology . 2005;128:1579–1605.

SAMPLE